Venus Remedies Ltd 2019 AR2
The report highlights Venus Remedies Limited's performance and strategic initiatives for the fiscal year 2018-19. Despite facing financial challenges and subdued numbers, the company remained cash flow positive with an EBITDA of ₹41.75 crore. Key highlights include the presentation of Phase-3 Clinical Trials for its flagship product Elores at IDWeek 2018 and participation in the U.S. Government's Antimicrobial Resistance Challenge. The company also advanced its digital transformation by automating MIS reports and saving 500 man-hours per month, while continuing its commitment to antibiotic stewardship through the PLEA campaign.
Company: Venus Remedies Ltd
Sector: Health Care
Country: India
Year: 2019
Type: AR2
Pages: 152
Venus Remedies Ltd
Annual Report
The report highlights Venus Remedies Limited's performance and strategic initiatives for the fiscal year 2018-19. Despite facing financial challenges and subdued numbers, the company remained cash flow positive with an EBITDA of ₹41.75 crore. Key highlights include the presentation of Phase-3 Clinical Trials for its flagship product Elores at IDWeek 2018 and participation in the U.S. Government's Antimicrobial Resistance Challenge. The company also advanced its digital transformation by automating MIS reports and saving 500 man-hours per month, while continuing its commitment to antibiotic stewardship through the PLEA campaign.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees